These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 27832783)

  • 1. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
    Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
    Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma.
    Szczyrba J; Nolte E; Wach S; Kremmer E; Stöhr R; Hartmann A; Wieland W; Wullich B; Grässer FA
    Mol Cancer Res; 2011 Jun; 9(6):791-800. PubMed ID: 21593139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
    Gao Q; Zheng J
    Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
    J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
    Xue D; Lu H; Xu HY; Zhou CX; He XZ
    J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
    Feng Q; He P; Wang Y
    Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
    Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
    Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
    Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG
    Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.
    Xiao L; Zhou H; Li XP; Chen J; Fang C; Mao CX; Cui JJ; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2016 Jun; 7(26):40038-40046. PubMed ID: 27223073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
    Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
    J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.
    Selth LA; Das R; Townley SL; Coutinho I; Hanson AR; Centenera MM; Stylianou N; Sweeney K; Soekmadji C; Jovanovic L; Nelson CC; Zoubeidi A; Butler LM; Goodall GJ; Hollier BG; Gregory PA; Tilley WD
    Oncogene; 2017 Jan; 36(1):24-34. PubMed ID: 27270433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.
    Lu X; Gan Q; Gan C; Zheng Y; Cai B; Li X; Li D; Yin G
    Life Sci; 2021 Jun; 274():118303. PubMed ID: 32841663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.
    Yan H; Li H; Li P; Li X; Lin J; Zhu L; Silva MA; Wang X; Wang P; Zhang Z
    J Exp Clin Cancer Res; 2018 Sep; 37(1):237. PubMed ID: 30249278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer.
    Yu SJ; Hu JY; Kuang XY; Luo JM; Hou YF; Di GH; Wu J; Shen ZZ; Song HY; Shao ZM
    Clin Cancer Res; 2013 Mar; 19(6):1389-99. PubMed ID: 23340296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Lee HC; Ou CH; Huang YC; Hou PC; Creighton CJ; Lin YS; Hu CY; Lin SC
    Oncogene; 2021 Apr; 40(13):2407-2421. PubMed ID: 33664454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.